Active pharmaceutical ingredients near Aachen
BBT Biotech GmbH in Baesweiler near Aachen in Germany is a Contract Service Organization focused on the development and production of active pharmaceutical ingredients for the pharmaceutical industry. BBT produces among others Streptokinase, Urokinase, HCG, HMG, FSH and Aprotinin.
The company
BBT Biotech GmbH is a manufacturer in the globally growing biopharmaceutical industry. We have sophisticated know-how in the production of therapeutically relevant, healthy microorganisms and special protein purification methods, all developed in-house. The combination of several production steps offered by us, combined with perfect process technology and state-of-the-art control systems, ensures custom-tailored, high-standard products.
Manufacturing takes place under regulatory requirements (GMP; Good Manufacturing Practice) resulting in the highest quality and technical standards. For proteins and microorganisms, we own the manufacturing authorization according to the AMG (Arzneimittelgesetz; German Drug Law).
The product range includes microorganisms and proteins for the international pharmaceutical industry as well as for the health-care and feed-additives industry. Viable microorganisms and proteins are offered not only in bulk but also in finished dosage forms.
For more information about our products click here.
Additionally, we offer the complete services regarding microorganisms and proteins: From contract development to contract manufacturing, from research to GMP quality.
BBT is part of the group of companies of the Pharma-Zentrale (https://www.pharma-zentrale.de/index.html).
Pharma-Zentrale was founded in 1953 and is located in Herdecke, North Rhine-Westphalia, Germany. Even today the company is a family business, representing a group of subsidiaries, each one a successful specialist in its particular pharmaceutical or biotechnological businesses. The group of companies includes Ardeypharm, Dr. Poehlmann & Co. and Dr. Ponsold Pharma.
Our strategy, facilities and technologies
In the European Union and the USA more than 100 therapeutic proteins are approved for clinical use. In the treatment of patients, active substance availability is a main bottleneck. Currently, too few active substances are produced for the global market – e.g. 70% of the worldwide produced insulin is used by 30% of all potential insulin users. This leads to 70% under supplied patients. Urokinase – one of our products is also a rare active substance. Additional to that the interwoven global supply chains in this market are quite challenging.
BBT is taking up this challenge: Our vision is to be one of the leading companies in development and manufacture of well-established active substances for medicinal devices and medicinal products.
Our mission is to make biological medicinal products more accessible to patients all over the world through the manufacture of well-established APIs for new applications.
To meet this challenges BBT Biotech GmbH has extensive scientific and technological know-how in bioprocess development, GMP production, quality control, regulatory and quality assurance and international sales of biopharmaceuticals and the resources, capacities and expertise to execute your project.
BBT Biotech GmbH can act as your Contract Service Organization (CSO) partner to outsource all or a part of the corresponding work packages.